23andMe Is Sharing Its 5 Million Clients’ Genetic Data with Drug Giant GlaxoSmithKline

By Drugs, Pharmaceutical

23andMe Is Sharing Its 5 Million Clients’ Genetic Data with Drug Giant GlaxoSmithKline

Popular genetics-testing company 23andMe is partnering with drug giant GlaxoSmithKline to use people’s DNA to develop medical treatments, the company announced in a blog post yesterday (July 25).

During the four-year collaboration, the London-based GlaxoSmithKline will use 23andMe’s genetic database to zero in on possible targets and treatments for human disease.

https://www.livescience.com/63173-23andme-partnership-glaxosmithkline.html

GSK to use 23andMe’s DNA library in drug development

https://www.engadget.com/amp/2018/07/26/gsk-23andme-dna-database-drug-development/

More from tokioX :

  1. Japan: Gene therapy drug “Solgensma” approved: 200 million yen per dose
  2. Japan: anti-influenza drug, ‘Avigan Tablet’ recommended: Fujifilm Development
  3. Chinese Alzheimer’s drug hits the market
  4. U.S. Government Sues Gilead over Alleged Infringement on HIV Prevention Drug
  5. 💊Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
  6. 💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
  7. アレイ バイオファーマ社、進行期悪性黒色腫についてbinimetinibおよびencorafenibの新薬承認申請をFDAに提出 ( Array BioPharma Submits New Drug Applications to FDA for Binimetinib and Encorafenib in Advanced Melanoma